__NUXT_JSONP__("/drugs/Axitinib", (function(a,b,c,d,e,f){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.",inn:b,marketingAuthorisationDate:"2012-09-03 00:00:00",marketingAuthorisationHolder:"Pfizer Europe MA EEIGÂ ",medicineName:c,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Finlyta"}],fdaDrugLabel:[{brand:d,indication:e,manufacturer:"Pfizer Laboratories Div Pfizer Inc",splSetId:"84137882-e000-47da-bd5b-fa76ab3c76f9"},{brand:d,indication:e,manufacturer:"U.S. Pharmaceuticals",splSetId:"8a903e31-936e-4ed7-8a59-59f32374f338"}],id:a,nciThesaurus:{casRegistry:"319460-85-0",chebiId:"",chemicalFormula:"C22H18N4OS",definition:"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.",fdaUniiCode:"C9LVQ0YUXG",identifier:"C38718",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C159198","C159199","C93259"],synonyms:["AG-013736","AG013736","AXITINIB",a,c,"N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide",b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAxitinib",extension:".json",createdAt:f,updatedAt:f}}],fetch:{},mutations:void 0}}("Axitinib","axitinib","Inlyta","INLYTA","1 INDICATIONS AND USAGE INLYTA is a kinase inhibitor indicated: in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma. 1.2 Second-Line Advanced Renal Cell Carcinoma INLYTA as a single agent is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.","2021-10-30T13:39:43.223Z")));